Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.32

+1.4%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.09B
EPS-0.5300
P/E Ratio-10.05
Earnings Date08/06/2026

svra

Other Non-Cash Items

Last Annual Value

-1.71M

3-Year CAGR

-71%

5-Year CAGR

-5%

10-Year CAGR

-26%

Savara Inc.

Savara Inc. Competitors Analysis of Other Non-Cash Items

SVRA · NASDAQ
CompanyOther Non-Cash Items
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
-1.71M
N/AN/AN/A 
515.00K
N/A5.2%28.5%
41.99M
N/A111.8%75.0%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
-1.86M
N/AN/AN/A
895.00K
-60.1%N/AN/A
1.20M
72.3%-2.0%N/A
-2.12M
N/AN/AN/A
-4.83M
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
-1.70M
N/AN/AN/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.3249, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.3249